• T SAI LAKSHMI SRIKALA Department of Pharmacy Practice, Anurag Pharmacy College, Kodad, Suryapet, Telangana, India.
  • T PRAVEEN KUMAR Department of Pharmaceutics, Anurag Pharmacy College, Kodad, Suryapet, Telangana, India.




corona virus, ELISA, Monoclonal antibodies (mAbs), Dromedary camels, WHO, Wuhan City


Middle East Respiratory Syndrome (MERS), having a high demise rate, which radiate from the Middle East. Novel Coronavirus is the causative living being for MERS and (2019-nCoV) was recognized infection by Chinese experts on January 7. On December 31, 2019, the WHO China Country Office was educated regarding instances of pneumonia of obscure etiologic (obscure reason) identified in Wuhan City, Hubei Province of China. Besides, MERS-CoV first found in dromedary camels and in bats, people. Proof recommends that animals are acting as host for MERS-CoV and transmitting the malady to people. Till the finish of November 2019, an aggregate of 2494 lab instances of MERS, were recorded which incorporates 858 deaths around the world. At present, no drug or immunization is accessible for MERS. As we knew that prevention is better than cure, taking precautions before attacking of the disease is the best way of preventing disease. In this study, we discussed about the pathological aspects, treatment strategies, and precautions of the disease.


Available from: https://www.who.int/health-topics/coronavirus

Available from: https://www.who.int/emergencies/mers-cov/en

World Health Organization. WHO MERS-CoV Global Summary and Assessment of Risk, Geneva, Switzerland: World Health Organization; 2018.

Woo PC, Lau SK, Li KS, Tsang AK, Yuen KY. Genetic relatedness of the novel human group C betacoronavirus to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5. Emerg Microb Infect 2012;1:1-5.

Kayali G, Peiris M. A more detailed picture of the epidemiology of Middle East respiratory syndrome coronavirus. Lancet Infect Dis 2015;15:495-7.

Milne-Price S, Miazgowicz KL, Munster VJ. The emergence of the Middle East respiratory syndrome coronavirus. Pathog Dis 2014;71:121-36.

Watson JT, Hall AJ, Erdman DD, Swerdlow DL, Gerber SI. Unraveling the mysteries of Middle East respiratory syndrome coronavirus. Emerg Infect Dis 2014;20:1054.

Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015;386:995-1007.

Chan JF, Lau SK, Woo PC. The emerging novel Middle East respiratory syndrome coronavirus: The “knowns” and “unknowns”. J Formosan Med Assoc 2013;112:372-81.

WHO MERS-CoV Research Group. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr 2013;5:30127ddb8.

Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 2005;69:635-64.

Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV a target for vaccine and therapeutic development. Nat Rev Microbiol 2009;7:226-36.

Wang N, Shi X, Jiang L, Zhang S, Wang D, Tong P, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013;23:986.

Matsuyama S, Ujike M, Morikawa S, Tashiro M, Taguchi F. Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Proc Natl Acad Sci 2005;102:12543-7.

Perlman S, Netland J. Coronaviruses post-SARS: Update on replication and pathogenesis. Nat Rev Microbiol 2009;7:439-50.

Sawicki SG, Sawicki DL, Siddell SG. A contemporary view of coronavirus transcription. J Virol 2007;81:20-9.

Lee H, Lei H, Santarsiero BD, Gatuz JL, Cao S, Rice AJ, et al. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV. ACS Chem Biol 2015;10:1456-65.

De Haan CA, Rottier PJ. Molecular interactions in the assembly of coronaviruses. Adv Virus Res 2005;64:165-230.

Balachandran S, Roberts PC, Brown LE, Truong H, Pattnaik AK, Archer DR, et al. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity 2000;13:129-41.

Kato H, Takahasi K, Fujita T. RIG-I-like receptors: Cytoplasmic sensors for non-self RNA. Immunol Rev 2011;243:91-8.

Anwar MA, Basith S, Choi S. Negative regulatory approaches to the attenuation of Toll-like receptor signaling. Exp Mol Med 2013;45:11.

Krishnan J, Selvarajoo K, Tsuchiya M, Lee G, Choi S. Toll-like receptor signal transduction. Exp Mol Med 2007;39:421-38.

Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001;413:732-8.

Niemeyer D, Zillinger T, Muth D, Zielecki F, Horvath G, Suliman T, et al. Middle East respiratory syndrome coronavirus accessory protein 4a is a Type I interferon antagonist. J Virol 2013;87:12489-95.

Siu KL, Yeung ML, Kok KH, Yuen KS, Kew C, Lui PY, et al. Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response. J Virol 2014;88:4866-76.

Roush S, Fast H, Miner CE, Vins H, Baldy L, McNall R, et al. National Center for Immunization and Respiratory Diseases (NCIRD) Support for Modernization of the Nationally Notifiable Diseases Surveillance System (NNDSS) to Strengthen Public Health Surveillance Infrastructure in the US. In: 2019 CSTE Annual Conference CSTE; 2019.

Falzarano D, De Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013;19:1313-7.

Gross AE, Bryson ML. Oral ribavirin for the treatment of noninfluenza respiratory viral infections: A systematic review. Ann Pharmacother 2015;49:1125-35.

Jonasch E, Haluska FG. Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities. Oncologist 2001;6:34.

Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden FG, Al-Omari A, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: A study protocol. Springerplus 2015;4:709.

Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. J Infect Dis 2015;211:80-90.

Winkler AM, Koepsell SA. The use of convalescent plasma to treat emerging infectious diseases: focus on Ebola virus disease. Curr Opin Hematol 2015;22:521-6.

Modjarrad K. Treatment strategies for Middle East respiratory syndrome coronavirus. J Virus Erad 2016;2:1-4.

Warren T, Jordan R, Lo M, Soloveva V, Ray A, Bannister R, et al. Nucleotide prodrug GS-5734 is a broad-spectrum filovirus inhibitor that provides complete therapeutic protection against the development of Ebola virus disease (EVD) in infected non-human primates. Open Forum Infect Dis 2015;2:LB-2.

Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014;508:402-5.

Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 2014;58:4885-93.

Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 2015;212:1904-13.

Gao J, Lu G, Qi J, Li Y, Wu Y, Deng Y, et al. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome corona virus. J Virol 2013;87:13134-40.

Command and Control Centre. Middle East Respiratory Syndrome Corona Virus; Guidelines for Healthcare Professionals. Vol. 5. Ministry of Health; 2018. p. 7-9.



How to Cite

SRIKALA, T. S. L., & KUMAR, T. P. (2021). EPIDEMIOLOGICAL AND CLINICAL CHARACTERISTICS OF 2019 NOVEL CORONA VIRUS: A REVIEW. Innovare Journal of Sciences, 9(6), 1–6. https://doi.org/10.22159/ijs.2021.v9i6.40448



Review Article(s)